Discontinuation of angiotensin converting enzyme inhibitors (ACEIs) as a potential marker for adverse drug reactions (ADRs)

Background: ACEI-induced ADRs are the main reason to discontinue ACEI treatment. In prescription databases, information on ADRs is not available; therefore it is necessary to identify proxies for ADRs in such databases to study risk factors for ADRs. Objectives: To study prescription patterns for ACEIs as potential marker for ACEI-induced ADRs. Methods: A cohort of patients starting ACEI from 2000 to 2011 was identified within the Rotterdam Study, (a prospective population-based cohort study of approximately 15,000 individuals aged 45 years and older). Medication dispensing data on daily basis were obtained from the fully computerized linked pharmacies. Participants were followed from the start of ACEI treatment until the end of study period, death or moving out of the area, whichever came first. Patients were classified into 4 mutually exclusive groups: continuous users, discontinued users, switchers to angiotensin receptor blockers (ARBs), and switchers to other antihypertensives. For continuous use or switching, the maximum time interval between two prescription periods was set at 3 or 6months. Patients without a prescription for antihypertensives, 3 or 6months after the end date of the last ACEI prescription were classified as discontinued users. Primary care physician files were searched for reasons of ACEI discontinuation for patients who discontinued or switched ACEIs. Clinical events were classified as definite ADRs (73.5% cough, 3% angioedema, 23.5%others), probable ADRs, possible ADRs and definite non-ADRs. Positive predictive values (PPVs) of the prescription patters of the 3 groups for ADRs were calculated. Results: Totally 1132 patients were included. The PPV for a definite ADR was 56.1% in switchers to ARBs, while the PPVs for switchers to other antihypertensives, and discontinued users were 39.5% and 19.5%. Including probable and possible ADRs, increased the PPVs for switchers to ARBs to 68.3% and 90.5%. A 6-month time interval gave slightly higher PPVs compared to a 3-month interval (maximum 6.1% higher). Conclusions: This study showed that switching from ACEI to ARB is the best marker for ACEI-induced ADRs in prescription databases